06.19.26 -- The Future Of Continuous Is Integrated Manufacturing: The 4 Misconceptions About A Lean Process

Early collaboration with an expert partner streamlines HME projects through optimized formulation, strong scale‑up, solid analytics, and adaptable technologies that boost performance.

Physiologically based pharmacokinetic (PBPK) modeling advancements are helping drug sponsors mitigate risk in preclinical and clinical studies through early identification of poor absorption properties.

RT-ddPCR offers a powerful, flexible approach to precise RNA quantification. Learn how one-step and two-step workflows improve sensitivity and efficiency in your gene expression studies.

What is actually behind the procurement of a pharmaceutical labeling machine and how does the process work? You can find out here what the path to your pharmaceutical labeling machine looks like.

Drug formulations demand more than single‑point viscosity data. Explore how rheology reveals stability, flow, and structural behavior across suspensions, topicals, and injectables.

Targeted impurity identification and purification redesign dramatically improved yield, reduced process complexity, and enabled reliable API supply for Phase II clinical development.

Discover the key advantages of stick-pack formats for pharmaceuticals and nutraceuticals, from enhanced product safety and cost-efficiency to improved compliance and marketability.

Sustainable amorphous dispersion cuts cost, risk, and timelines by removing solvent waste, simplifying manufacturing, strengthening supply chains, and scaling efficiently to commercialization.

Peptide therapeutics from early chemical breakthroughs to today’s metabolic drugs, highlighting scientific, clinical, and manufacturing advances shaping modern drug development.

See how a U.S.-based CDMO combines advanced infrastructure, quality-driven processes, and flexible manufacturing to support pharmaceutical development and commercial supply.

Uncover how a scientifically grounded framework for early-phase CMC development, integrating QbD and proactive risk management, helps de-risk drug development and accelerate molecules to market.

Bridging the gap between initial startup and long-term sustainability requires a unified strategy. Transform early readiness metrics into a durable operating system that drives continuous performance.

Shift from basic compliance to a strategic GxP culture. Delve into how intentional, role-specific training and leadership support reduce risks and improve business outcomes in this video.

Leverage a platform-based analytical development strategy to accelerate ADC IND readiness through early CQA identification, reduced development risk, and streamlined progression from development to patients.

Rushed OSD formulation decisions create costly downstream failures. Gain insight into how strategic early-phase planning reduces CMC holds, scale-up risks, and regulatory delays.

Master USP <800> compliance by transitioning from standalone equipment to an integrated system design. Review key protocols for a multi-layered strategy to mitigate cumulative drug risks.